Achievements

•    Led the development and validation of OECD-approved in vitro assays, including the Eye Irritation Test (OECD TG 492),  Reconstructed Skin Micronucleus and Comet Assays, and Reconstructed Skin Phototoxicity Testing (OECD TG 498)
•    Secured and managed NIH/SBIR Phase I and II research grants, leading to the successful commercialization of multiple in vitro models
•    Expanded the applicability domain of OECD TG 431, enabling more precise skin corrosion subcategorization
•    Developed and optimized first-in-class 3D tissue models for kidney, ocular, mucosal, melanoma, and airway research
•    Established a human reconstructed proximal tubular epithelium model, advancing ADME and kidney injury research
•    Pioneered a non-animal inhalation toxicity testing method, using human respiratory EpiAirway 3D models
•    Played a key role in integrating NAMs and in vitro models into OECD, REACH, and ECVAM regulatory frameworks
•    Secured multimillion-dollar funding for R&D initiatives, collaborating with global stakeholders and industry leaders
•    Provided strategic consulting on toxicology, regulatory compliance, and biotechnology trends for investors and corporate clients
•    Managed GLP and GMP-compliant studies, ensuring regulatory adherence and high-quality toxicology data
•    Developed novel preclinical in vitro assays for drug discovery, safety assessment, and disease modeling
•    Advised on market positioning and regulatory adoption of alternative toxicology methods for biotechnology and pharmaceutical industries
•    Represented companies at scientific committees, international conferences, and business meetings, shaping industry standards
•    Led multidisciplinary teams, mentoring scientists and fostering cross-functional collaborations to advance in vitro technologies
•    Evaluated and validated new testing technologies, driving regulatory acceptance and adoption across industries